Brief: Cantargia Publishes Nadunolimab CANFOUR Study Data
26/06/2026 07:06
BRIEF-Cantargia Publishes Nadunolimab CANFOUR Study Data June 26 (Reuters) - Cantargia AB CANTA.ST:
ANNOUNCES PUBLICATION OF NADUNOLIMAB CANFOUR STUDY DATA IN JCI INSIGHT
DATA SUPPORT NADUNOLIMAB POTENTIAL IN FUTURE PANCREATIC CANCER TREATMENT STRATEGIES
SURROGATE ANTIBODY STRONGLY INHIBITS TUMOR GROWTH IN PRECLINICAL PANCREATIC CANCER MODEL
Source text: ID:nMFN9vmqPt
Further company coverage: CANTA.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Cantargia AB
See all newsBrief: Cantargia Publishes Nadunolimab CANFOUR Study Data
Brief: Cantargia Announces Outcome Of Rights Issue, Raising About SEK 75 Mln
Brief: Cantargia Carries Out Rights Issue, Enters Loan Agreement
Brief: Cantargia Q1 Operating Loss Narrows To SEK 36.9 Mln
Brief: Cantargia: Early Results From Phase 1B/2A Nadunolimab Trial In MDS And AML